Metis TechBio stock
Price history
−69.38% over the periodFull history: from $21.70 (May 15, 2026) to $6.65 (November 20, 2026), −69.38%.
Show chart data
Closing prices adjusted for splits: one row per trading day.
| Date | Close |
|---|---|
| November 20, 2026 | $6.65 |
| November 13, 2026 | $8.36 |
| November 6, 2026 | $10.99 |
| October 30, 2026 | $11.15 |
| October 23, 2026 | $10.58 |
| October 16, 2026 | $11.92 |
| October 9, 2026 | $14.57 |
| October 2, 2026 | $18.52 |
| September 25, 2026 | $15.61 |
| September 18, 2026 | $17.40 |
| September 11, 2026 | $15.42 |
| September 4, 2026 | $13.82 |
| August 28, 2026 | $13.88 |
| August 21, 2026 | $14.24 |
| August 14, 2026 | $12.11 |
| August 7, 2026 | $11.12 |
| July 31, 2026 | $10.06 |
| July 24, 2026 | $11.25 |
| July 17, 2026 | $10.11 |
| July 10, 2026 | $12.48 |
| July 3, 2026 | $13.93 |
| June 26, 2026 | $13.05 |
| June 18, 2026 | $14.41 |
| June 12, 2026 | $13.19 |
| June 5, 2026 | $14.06 |
| May 29, 2026 | $14.78 |
| May 22, 2026 | $16.88 |
| May 15, 2026 | $21.70 |
At a glance
The company
Develops AI-driven nanomaterials and NanoForge technologies for delivering active agents in pharmaceutical and biotech research
Latest results
Quarter to June 30, 2026 · EPS -¥0.17
Next event
TickerLandia's take on Metis TechBio
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−77.84% from the 52-week high
Analysts · 4 analysts
Average target$24.63+270.71% vs. price
Buy 4 · Hold 0 · Sell 0
TickerLandia Fingerprint: Metis TechBio
Compared with similar companies: very weak momentum, very high risk, and very low earnings stability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Priceaverage48
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 33.7 82 Price/book 2.45 15 Profitabilityaverage43
How much it earns on revenue and capital.
Metric Value Position in group ROE 229.5% 98 ROA −20.0% 12 Gross margin 98.9% 93 Operating marginabove 100%: likely one-off items −131.2% 11 Net marginabove 100%: likely one-off items −137.0% 2 Earnings stabilityvery low16
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 31,028.9% 3 Loss-making yearscounts in reverse: lower means more earnings stability 4 of 5 annual reports 30 Growthhigh78
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −28.58% 38 Revenue growth (year over year) +13,398.90% 99 Average revenue growth (3 years) +474.42% 96 Financial strengthaverage56
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −11.8 14 Debt/equitycounts in reverse: lower means more financial strength 0.06 61 Current ratio 17.7 94 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak3
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) −57.75% 3 Relative strength (3 months) −49.20% 2 Riskvery high95
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 73.7% 97 Beta (1 year) 1.88 90 Volatility (60 days) 109.2% 100
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Metis TechBio is cheaper than similar companies
Metis TechBio's Price/book: 2.45, −47% against the median of a group of 11 similar companies (4.64).
Compared with 11 similar companies
| Metric | Metis TechBio | Position in the group | Band |
|---|---|---|---|
| Operating margin | -131.2% | Low | |
| ROE | 229.5% | High | |
| Debt/equity | 0.06 | Middle | |
| Price/book | 2.45 | Low | |
| Net margin | -137.0% | Low |
Grey band: the middle half of the group; tick: the median; dot: Metis TechBio. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥77.15M
Latest quarter · Q2 2026
Net income
-¥76.6M
Latest quarter · Q2 2026
Quarterly net margin
-99.3%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $8.69B
- EPS
- -$0.38
- Volume
- 15.23M
- Daily trading
- €7.82M
- Dividend yield
- 0.00%
How Metis TechBio is changing
All resultsRevenue grew 474.4% a year on average over the last 3 years
Operating margin rose from −68,012.5% to −356.6%
Shares outstanding down 20.9% in 3 years
Returns
Metis TechBio returns
| Period | Metis TechBio | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −40.62% | −6.10% | $594 |
| 6 months | −63.08% | −12.63% | $369 |
Over the last 6 months it has done better than 3% of the stocks in the Materials sector.
Price only, without dividends.
The chart in detail
Metis TechBio: technical analysis
The price is 73.7% below its all-time closing high ($25.24, May 14, 2026).
- RSI (14 sessions)
- 24
- Below 30: a strong fall in a short time
- vs 50-session average
- −48.47%
Active signals
Close below the low of the previous 55 sessions.
RSI below 30: the stock has fallen a lot in a short time.
since November 17, 2026
Support and resistance
Price areas where Metis TechBio has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$12.29+84.88%2 touches, last on October 29, 2026
- Resistance$11.56+73.89%4 touches, last on November 10, 2026
- Resistance$9.74+46.56%4 touches, last on November 3, 2026
- Last price$6.65
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved more than the Hang Seng.
- Beta (1 year) vs Hang Seng
- 1.88
- Volatility (60 sessions, annualised)
- 109.2%
- Largest fall in the last year
- −73.67%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Metis TechBio and its competitors
Metis TechBio develops AI-driven nanomaterial tools for delivering active agents across carbon-based life forms, with research work in Chinese Mainland and the United States. Its NanoForge suite pairs a lipid compound collection with machine-learning models, molecular simulation and automated screening systems. Further platforms named AiTEM, AiLNP and AiRNA model how nanoscale particles interact, supporting the design, optimization and validation of nanomaterials and their payloads.
- Headquarters
- Beijing, China
- Employees
- 150
- Founded
- 2020
- Chief executive
- Tsai-Ta Lai
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Metis TechBio7666 | $1.11B | -131.2% | — | −63.08% |
| MesoblastMSB | $1.48B | -42.6% | — | −14.82% |
| Neuren PharmaceuticalsNEU | $1.83B | 19.9% | 144.0 | +68.84% |
| InSilico Medicine Cayman TopCo3696 | $2.59B | -6.9% | — | −36.46% |
| Telix PharmaceuticalsTLX | $2.92B | 6.2% | 92.3 | −7.71% |
| 3SBio1530 | $4.56B | 60.3% | 3.90 | −34.08% |
Same industry or related industries, similar size. Compare Metis TechBio with its competitors · Full profile
